Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycoside dosing: a randomized prospective study

D J Kemme1, C I Daniel

  • 1Department of Medicine, Saint Joseph Hospital, Denver, Colo 80218.

Southern Medical Journal
|January 1, 1993
PubMed
Summary

This study found that predictive dosing for aminoglycosides did not improve clinical outcomes or reduce toxicity in gram-negative infections. Further research is needed to confirm the benefits of aminoglycoside dosing services.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of the art therapy of mycosis fungoides and Sézary syndrome.

Oncology (Williston Park, N.Y.)·1992
Same author

Subendocardial arteriovenous malformation in a patient with unstable angina.

Clinical cardiology·1991
See all related articles

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Infectious Diseases
  • Nephrology

Background:

  • Clinical benefits of aminoglycoside dosing services are suggested but not prospectively documented.
  • Aminoglycosides are critical for treating gram-negative infections but require careful dosing to minimize toxicity.

Purpose of the Study:

  • To prospectively evaluate the clinical efficacy and nephrotoxicity of different aminoglycoside dosing methods.
  • To compare physician dosing, predictive dosing, and individual pharmacokinetic dosing.

Main Methods:

  • A randomized trial initially included three dosing groups: physician, predictive, and individual pharmacokinetic dosing.
  • The individual pharmacokinetic dosing group was eliminated due to erratic aminoglycoside levels.
  • Analysis focused on 41 patients with gram-negative infections receiving aminoglycosides for >2 days, comparing physician vs. predictive dosing.

Related Experiment Videos

Main Results:

  • Predictive dosing resulted in significantly higher peak and lower trough aminoglycoside levels compared to physician dosing.
  • No significant differences were observed in the incidence of nephrotoxicity or clinical response between the two methods.
  • Confidence intervals indicated no major clinical benefit for predictive dosing in this patient group.

Conclusions:

  • The predictive aminoglycoside dosing method did not demonstrate superior clinical efficacy or safety over standard physician dosing.
  • Previous findings suggesting improved outcomes with aminoglycoside dosing services are questioned.
  • Larger prospective studies are recommended to definitively assess the value of aminoglycoside dosing services.